APPLICATION OF NOVEL CORONAVIRUS VACCINE PEPTIDE AND NANOEMULSION PREPARATION THEREOF IN PREVENTION OF NOVEL CORONAVIRUS WILD AND MUTANT STRAINS
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Jan 9, 2025
app pub date -
May 30, 2022
filing date -
May 30, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully